查看购物车
  • Traditional Chinese
  • English
  • Japanese
临床试验中人工智慧的全球市场：按产品、按功能、按阶段、按部署模式、按适应症、按技术、按应用、按最终用户、按地区 - 到 2030 年的预测
市场调查报告书
商品编码
1618952

临床试验中人工智慧的全球市场：按产品、按功能、按阶段、按部署模式、按适应症、按技术、按应用、按最终用户、按地区 - 到 2030 年的预测

AI in Clinical Trials Market by Function, Phase, Indication, Tool, End-User & Region - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 373 Pages | 订单完成后即时交付

价格

临床试验中人工智慧的市场规模预计将从2024年的13.5亿美元增加到2030年的27.4亿美元，2024年至2030年的复合年增长率为12.4%。

对提高疗效、更快的患者招募和准确的资料分析的需求不断增长，正在推动临床试验市场中的人工智慧。人工智慧驱动的解决方案可以帮助缩短临床试验各个阶段的持续时间，并使用预测模型和参与策略来提高患者保留水准。此外，穿戴式装置和电子病历系统的使用越来越多，将透过促进过程中每个阶段的监控来增强人工智慧在临床试验中的应用。然而，监管规范、过高的实施成本以及对资料外洩的担忧等一些障碍，阻碍了人工智慧在临床试验中的全面使用。

调查范围
调查年份 2022-2030
基准年 2023年
预测期 2024-2030
考虑单位 金额（美元）
按细分市场 按产品、按功能、按阶段、按部署模式、按指示、按技术、按用途、按最终用户、按区域
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东非洲

在应用人工智慧技术进行临床试验的所有适应症中，感染疾病很可能是成长最快的。由于世界需要更快、更好的解决流行病等疾病爆发的方案，这些发展进展非常迅速。人工智慧加快患者登记流程、增强预测并更好地建立临床试验。感染疾病控制宣传活动的增加导致先进技术（尤其是人工智慧）的使用显着增加。

从最终用户来看，临床试验市场中的人工智慧分为製药和生物製药公司、研究机构和实验室、医疗保健提供者、CRO 和医疗设备製造商。大部分市场占有率由製药和生物製药公司占据。这是因为研发成本非常高，这反过来又增加了人工智慧的应用，以加快药物开发流程、更好的临床试验设计以及增强公司的患者招募。此类人工智慧系统将有助于对大资料集进行复杂的分析，加快产品推向市场的速度，并控制不断增加的成本，这对于赢得製药业的竞争至关重要。

本报告研究了临床试验市场中的全球人工智慧，并透过产品、功能、阶段、部署模式、适应症、技术、用途、最终用户、区域和市场进入来分析趋势。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 介绍
  • 市场动态
  • 市场动态
  • 产业动态
  • 生态系分析
  • 案例研究分析
  • 价值链分析
  • 波特五力分析
  • 主要相关人员和采购标准
  • 监管状况
  • 专利分析
  • 技术分析
  • 价格分析
  • 2024-2025年重大会议和活动
  • 影响客户业务的趋势和颠覆
  • 未满足的需求和最终用户的期望
  • 投资金筹措场景
  • AI/生成AI对临床试验中AI市场的影响

第六章 临床试验中的人工智慧市场（依产品划分）

  • 介绍
  • 端对端解决方案
  • 利基解决方案
  • 技术提供者
  • 服务

第七章 临床试验中的人工智慧市场（按功能分）

  • 介绍
  • 招募受试者
  • 优化测试设计
  • 资料管理和品管
  • 不利事件的预测和检测
  • 药物再利用
  • 监理合规性

第八章 临床试验中的人工智慧市场（分阶段）

  • 介绍
  • I期临床试验
  • II期临床试验
  • III期临床试验
  • IV期临床试验

第九章 临床试验中的人工智慧市场（依部署方式）

  • 介绍
  • 云端基础的解决方案
  • 本地解决方案

第十章 临床试验中的人工智慧市场（按适应症）

  • 介绍
  • 肿瘤学
  • 神经系统疾病
  • 心血管疾病
  • 代谢性疾病
  • 感染疾病
  • 免疫疾病
  • 其他的

第十一章 临床试验中的人工智慧市场（按技术）

  • 介绍
  • 机器学习
  • 自然语言处理
  • 电脑视觉
  • 机器人流程自动化
  • 其他的

第十二章 临床试验中的人工智慧市场（按应用分）

  • 介绍
  • 生物标誌物
  • 细胞/基因治疗
  • 再生医学
  • 医疗设备和诊断

第十三章临床试验中的人工智慧市场（按最终用户）

  • 介绍
  • 製药和生物製药公司
  • 研究机构/研究所
  • 医疗服务提供方
  • CRO
  • 医疗设备製造商

第十四章 临床试验中的人工智慧市场（分地区）

  • 介绍
  • 北美洲
    • 北美宏观经济前景
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 亚太宏观经济展望
    • 日本
    • 中国
    • 印度
    • 其他的
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东/非洲
    • 中东和非洲宏观经济前景
    • 海湾合作委员会国家
    • 其他的

第十五章竞争格局

  • 介绍
  • 主要参与企业的策略/优势
  • 2019-2023年收益分析
  • 2023 年市场占有率分析
  • 企业评估矩阵：主要参与企业，2023
  • 企业评估象限：Start-Ups/小型企业，2023 年
  • 公司评价及财务指标
  • 品牌/产品比较
  • 竞争场景

第十六章 公司简介

  • 主要参与企业
    • IQVIA INC.
    • DASSAULT SYSTEMES（MEDIDATA）
    • INSILICO MEDICINE
    • TEMPUS AI, INC.
    • NVIDIA CORPORATION
    • SAAMA
    • PHESI
    • PATHAI, INC.
    • UNLEARN.AI, INC.
    • DEEP6.AI
    • MICROSOFT
    • IBM
    • CONCERTAI
    • AICURE
    • MEDIAN TECHNOLOGIES
    • LANTERN PHARMA INC.
    • CITELINE, A NORSTELLA COMPANY
    • TRINETX, LLC
  • 其他公司
    • REVIVEMED INC.
    • EURETOS
    • VERISIM LIFE
    • TRIOMICS
    • ARDIGEN
    • QUANTHEALTH LTD.
    • DEEP GENOMICS

第十七章附录

Product Code: HIT 9229

The AI in clinical trials market is projected to reach USD 2.74 billion by 2030 from USD 1.35 billion in 2024, at a CAGR of 12.4% from 2024 to 2030. The growing demand for improvements in effectiveness, recruitment of patients in a shorter duration, and accurate analysis of data is the key factor fuelling the market for AI in clinical trials. Solutions powered by AI assist in shortening the duration of various phases of the trial and also in improving patient retention levels using predictive modelling and engagement strategies. In addition, the increase in use of wearables and EMR systems facilitates monitoring at every stage of the course, hence reinforcing the application of AI in trials. Nevertheless, a few obstacles including regulatory norms, prohibitively high cost of implementation and fears of data breach act as constraints hindering the full-scale use of AI in clinical trials.

Scope of the Report
Years Considered for the Study2022-2030
Base Year2023
Forecast Period2024-2030
Units ConsideredValue (USD)
SegmentsBy Offering, Function, Phase, Deployment Mode, Indication, Technology, Application, End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East Africa.

"Infectious diseases had the fastest growth rate in the AI in clinical trials market during the forecast period, by indication."

In the sector of conducting clinical studies with the application of AI technologies, it is likely that among all indications infectious diseases will experience the most rapid growth. Such development is very fast owing to the global appeal for quicker and better solutions against disease outbreaks such as the pandemic. AI speed up the patient enrolment process, enhance forecasting, better structure the trials all of which help to deal with fast spreading viruses in a common sense. There has been a significant rise in the use of advanced technologies especially AI owing to the increased campaigns of fighting infectious diseases.

"By end user, the pharmaceutical & biopharma companies to account for largest market share in 2023."

By end user, AI in clinical trials market is bifurcated into pharmaceutical & biopharma companies, research institutes & labs, healthcare providers, contract research organizations, and medical device manufacturers. The majority of the market share to be occupied by pharmaceutical & biopharma companies' segment. This is due to the great extent of research and development expenditure, which in turn raises the application of AI for faster drug development processes, better clinical trial designs as well as enhanced patient recruitment for the companies. Such AI systems are designed for such firms to help in a complex analysis of large data sets, quicken the introduction of products into the market, and control the ever-increasing costs which are very essential in winning the competition in the case of the pharmaceutical sector.

"Asia Pacific is estimated to register the highest CAGR over the forecast period."

The AI in clinical trials market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific AI in clinical trials market is projected to register highest CAGR during the forecast period. The Asia Pacific is benefiting from the fast-developing healthcare infrastructure, advances in AI technologies and expansion of clinical research. With countries such as China, India and Japan encouraging the use of AI in healthcare to facilitate large and varied populations and organize clinical trials more efficiently. Furthermore, owing to the favourable government policies, increasing proliferations of contract research organizations (CROs) and cheaper operation costs in the market relative to the Western regions, many multinational pharmaceutical companies are making it their business to invest in AI clinical trials within the region.

Breakdown of supply-side primary interviews by company type, designation, and region:

  • By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
  • By Designation: Managers (40%), Directors (35%), and Others (25%)
  • By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report:

    • IQVIA Inc. (US)
    • Saama. (US)
    • Dassault Systemes (Medidata) (France)
    • Phesi (US)
    • PathAI, Inc. (US)
    • Unlearn.ai, Inc. (US)
    • Deep6.ai (US)
    • Microsoft (US)
    • IBM (US)
    • NVIDIA Corporation (US)
    • Insilico Medicine (US)
    • ConcertAI. (US)
    • AiCure. (US)
    • Median Technologies. (France)
    • Lantern Pharma Inc. (US)
    • Citeline, a Norstella Company (US)
    • Tempus AI, Inc. (US)
    • TriNetX, LLC (US)
    • ReviveMed Inc. (US)
    • Euretos. (US)
    • VeriSIM Life. (US)
    • Triomics (US)
    • Ardigen (Poland)
    • QuantHealth Ltd. US)
    • DEEP GENOMICS. (Canada)

Research Coverage:

This research report categorizes the AI in clinical trials market by offerings (end-to-end solutions, niche solutions, technology providers and services), function (patient recruitment, trial design optimization, data management & quality control, adverse event prediction & detection, drug repurposing, and regulatory compliance), phase (phase I, phase II, phase III and phase IV), deployment mode (cloud-based solutions, and on-premise solutions), indication (oncology, neurological diseases, cardiovascular diseases, metabolic diseases, infectious diseases, immunology diseases, and others (gastrointestinal, respiratory & reproductive), technology (machine learning, NLP, computer vision, robotic process automation, and others), application (biomarkers, cell & gene therapy, regenerative medicine, and medical devices & diagnostics), end user (pharmaceutical & biotechnology companies, research institutes & labs, healthcare providers, contract research organizations (CROs), and medical device manufacturers) and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in clinical trials market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in clinical trials market. Competitive analysis of upcoming startups in the AI in clinical trials market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in clinical trials market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers: (Growing demand for faster and more efficient drug development), restraints (High costs associated with implementing AI solutions), opportunities (Increased focus on precision medicine), and challenges (Complexity of integrating AI into traditional clinical trial frameworks) influencing the growth of the AI in clinical trials market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in clinical trials market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the AI in clinical trials market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the AI in clinical trials market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as IQVIA Inc. (US), Dassault Systemes (Medidata) (France), Tempus AI, Inc. (US), Insilico Medicine (US), ConcertAI. (US), AiCure. (US) PathAI, Inc. (US), etc. among others in AI in clinical trials market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 SEGMENTS CONSIDERED
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key sources for secondary data
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key sources for primary data
      • 2.1.2.2 Objectives of primary research
      • 2.1.2.3 Key data from primary sources
      • 2.1.2.4 Key insights from primary experts
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 SUPPLY-SIDE REVENUE SHARE ANALYSIS
    • 2.2.2 PARENT MARKET APPROACH
    • 2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
    • 2.2.4 MARKET SEGMENT ASSESSMENT
    • 2.2.5 GEOGRAPHIC MARKET ASSESSMENT
  • 2.3 DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 AI IN CLINICAL TRIALS MARKET OVERVIEW
  • 4.2 AI IN CLINICAL TRIALS MARKET, BY REGION
  • 4.3 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER AND COUNTRY
  • 4.4 AI IN CLINICAL TRIALS MARKET: GEOGRAPHICAL SNAPSHOT
  • 4.5 AI IN CLINICAL TRIALS MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
  • 5.3 MARKET DYNAMICS
    • 5.3.1 DRIVERS
      • 5.3.1.1 Increasing demand for personalized treatments
      • 5.3.1.2 Support for decentralized and global trials
      • 5.3.1.3 Regulatory compliance and ethical considerations
      • 5.3.1.4 Automated document review for better regulatory compliance
      • 5.3.1.5 Focus on real-time data management and analysis
    • 5.3.2 RESTRAINTS
      • 5.3.2.1 Data privacy and security concerns
      • 5.3.2.2 Integration challenges with legacy systems and resistance from healthcare professionals
      • 5.3.2.3 High implementation cost and need for skilled AI professionals
    • 5.3.3 OPPORTUNITIES
      • 5.3.3.1 Use of predictive analytics in clinical trials
      • 5.3.3.2 Development of virtual control arms for faster trials
      • 5.3.3.3 Integrating natural language processing into clinical trials for data extraction
    • 5.3.4 CHALLENGES
      • 5.3.4.1 Addressing algorithm bias and fairness
      • 5.3.4.2 Insufficient technical expertise in AI-based solutions
  • 5.4 INDUSTRY TRENDS
    • 5.4.1 INCREASING ADOPTION OF DECENTRALIZED CLINICAL TRIALS
    • 5.4.2 RISING FOCUS ON AI-POWERED PATIENT RECRUITMENT AND RETENTION
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 CASE STUDY ANALYSIS
    • 5.6.1 AI-POWERED APPROACH TO OVERCOME CHALLENGES IN IPF DRUG DEVELOPMENT
    • 5.6.2 REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH ADVANCED MATCHING NETWORKS
    • 5.6.3 BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS
  • 5.7 VALUE CHAIN ANALYSIS
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 BARGAINING POWER OF SUPPLIERS
    • 5.8.2 BARGAINING POWER OF BUYERS
    • 5.8.3 THREAT OF SUBSTITUTES
    • 5.8.4 THREAT OF NEW ENTRANTS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.9.2 KEY BUYING CRITERIA
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 REGULATORY FRAMEWORK
  • 5.11 PATENT ANALYSIS
    • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN CLINICAL TRIALS
    • 5.11.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.12 TECHNOLOGY ANALYSIS
    • 5.12.1 KEY TECHNOLOGIES
      • 5.12.1.1 Machine learning
      • 5.12.1.2 Natural language processing
      • 5.12.1.3 Computer vision
    • 5.12.2 COMPLEMENTARY TECHNOLOGIES
      • 5.12.2.1 Internet of things
      • 5.12.2.2 Cloud computing
    • 5.12.3 ADJACENT TECHNOLOGIES
      • 5.12.3.1 Advanced genomics
  • 5.13 PRICING ANALYSIS
    • 5.13.1 INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023
    • 5.13.2 INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022-2024
  • 5.14 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.15 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • 5.16 UNMET NEEDS AND END-USER EXPECTATIONS
    • 5.16.1 UNMET NEEDS
    • 5.16.2 END-USER EXPECTATIONS
  • 5.17 INVESTMENT & FUNDING SCENARIO
  • 5.18 IMPACT OF AI/GEN AI ON AI IN CLINICAL TRIALS MARKET
    • 5.18.1 KEY USE CASES
    • 5.18.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 5.18.2.1 Case study
      • 5.18.2.2 Clinical trials market
      • 5.18.2.3 eClinical solutions market
      • 5.18.2.4 AI in biotechnology market
    • 5.18.3 USERS READINESS AND IMPACT ASSESSMENT
      • 5.18.3.1 User readiness
        • 5.18.3.1.1 Pharmaceutical & biopharmaceutical companies
        • 5.18.3.1.2 Contract research organizations
      • 5.18.3.2 Impact assessment
        • 5.18.3.2.1 User A: Healthcare providers
        • 5.18.3.2.2 User B: Research institutes & laboratories

6 AI IN CLINICAL TRIALS MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 END-TO-END SOLUTIONS
    • 6.2.1 COST-EFFECTIVENESS, IMPROVED EFFICIENCY, AND REDUCED HUMAN ERRORS TO DRIVE ADOPTION IN CLINICAL TRIALS
  • 6.3 NICHE SOLUTIONS
    • 6.3.1 HIGH FAILURE RATES OF CLINICAL TRIALS AND NEED FOR STREAMLINED PROCESSES TO FUEL MARKET GROWTH
  • 6.4 TECHNOLOGY PROVIDERS
    • 6.4.1 NEED TO ACCELERATE DRUG DEVELOPMENT PROCESSES AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH
  • 6.5 SERVICES
    • 6.5.1 CONSULTING SERVICES
      • 6.5.1.1 Consulting services to optimize trial design, enhance patient recruitment, and improve data management
    • 6.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
      • 6.5.2.1 Need for smooth integration and optimization of AI technologies to boost segment growth
    • 6.5.3 TRAINING & EDUCATION SERVICES
      • 6.5.3.1 Need for skilled talent for managing complex AI systems to augment segment growth
    • 6.5.4 POST-SALES & MAINTENANCE SERVICES
      • 6.5.4.1 Development of complex AI systems and need for continuous improvement in AI algorithms to drive segment growth

7 AI IN CLINICAL TRIALS MARKET, BY FUNCTION

  • 7.1 INTRODUCTION
  • 7.2 PATIENT RECRUITMENT
    • 7.2.1 PATIENT IDENTIFICATION & SCREENING
      • 7.2.1.1 Reduced patient screening time and better accuracy than human clinicians to drive market
    • 7.2.2 PATIENT ENGAGEMENT & RETENTION
      • 7.2.2.1 Better personalized communication and support for clinical trials to propel market growth
    • 7.2.3 SITE OPTIMIZATION
      • 7.2.3.1 Cost-effective and improved participant recruitment and retention to fuel segment growth
  • 7.3 TRIAL DESIGN OPTIMIZATION
    • 7.3.1 WORKFLOW MANAGEMENT
      • 7.3.1.1 Effective real-time tracking, automated reporting, and milestone monitoring to spur segment growth
    • 7.3.2 PREDICTIVE MODELING
      • 7.3.2.1 Ability to optimize trial design, predict risks, and identify effective treatment protocols to drive segment
    • 7.3.3 RISK MANAGEMENT
      • 7.3.3.1 AI-driven solutions for risk prediction to improve patient safety and data integrity
  • 7.4 DATA MANAGEMENT & QUALITY CONTROL
    • 7.4.1 FOCUS ON MAINTAINING DATA ACCURACY AND INTEGRITY IN CLINICAL TRIALS TO BOOST ADOPTION
  • 7.5 ADVERSE EVENT PREDICTION & DETECTION
    • 7.5.1 MITIGATING RISKS AND HARNESSING AI-DRIVEN ADVERSE EVENT DETECTION TO SPUR MARKET GROWTH
  • 7.6 DRUG REPURPOSING
    • 7.6.1 DRUG REPURPOSING TO VALIDATE HYPOTHESES AGAINST REAL-TIME PATIENT DATA IN RARE DISEASES
  • 7.7 REGULATORY COMPLIANCE
    • 7.7.1 COMPLEXITY OF GLOBAL REGULATORY ENVIRONMENTS AND NEED FOR FASTER DRUG APPROVALS TO AID MARKET GROWTH

8 AI IN CLINICAL TRIALS MARKET, BY PHASE

  • 8.1 INTRODUCTION
  • 8.2 PHASE I CLINICAL TRIALS
    • 8.2.1 FASTER PATIENT IDENTIFICATION AND RECRUITMENT TO PROPEL ADOPTION OF AI
  • 8.3 PHASE II CLINICAL TRIALS
    • 8.3.1 NEED FOR ACCURATE PREDICTION OF OPTIMAL DOSAGE IN PHASE II TRIALS TO BOOST USE OF AI
  • 8.4 PHASE III CLINICAL TRIALS
    • 8.4.1 NEED TO CHECK DRUG EFFICACY AND MONITOR ADVERSE REACTIONS TO AUGMENT MARKET GROWTH
  • 8.5 PHASE IV CLINICAL TRIALS
    • 8.5.1 AI TO ASSESS SAFETY AND LONG-TERM OUTCOMES OF TREATMENT IN LARGER PATIENT POPULATION UNDER PHASE IV TRIALS

9 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE

  • 9.1 INTRODUCTION
  • 9.2 CLOUD-BASED SOLUTIONS
    • 9.2.1 PUBLIC CLOUD-BASED SOLUTIONS
      • 9.2.1.1 Reduced need for costly on-premises infrastructure and better regulatory compliance to fuel adoption
    • 9.2.2 PRIVATE CLOUD-BASED SOLUTIONS
      • 9.2.2.1 Better security and personalization for sensitive data to propel segment growth
    • 9.2.3 MULTI CLOUD-BASED SOLUTIONS
      • 9.2.3.1 Use of advanced predictive modeling for patient recruitment and site performance optimization to drive market
    • 9.2.4 HYBRID CLOUD-BASED SOLUTIONS
      • 9.2.4.1 Better flexibility in data management to reduce resource requirements in clinical trials
  • 9.3 ON-PREMISES SOLUTIONS
    • 9.3.1 ON-PREMISES SOLUTIONS TO OFFER SECURE ENVIRONMENT FOR MANAGING SENSITIVE DATA AND RUNNING COMPLEX ALGORITHMS

10 AI IN CLINICAL TRIALS MARKET, BY INDICATION

  • 10.1 INTRODUCTION
  • 10.2 ONCOLOGY
    • 10.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE DRUGS TO DRIVE SEGMENT GROWTH
  • 10.3 NEUROLOGICAL DISEASES
    • 10.3.1 COMPLEXITY OF NEUROGENERATIVE DISORDERS AND SHORTAGE OF DRUGS FOR PARKINSON'S DISEASE TO SPUR MARKET GROWTH
  • 10.4 CARDIOVASCULAR DISEASES
    • 10.4.1 RISING DEMAND FOR NOVEL CARDIOVASCULAR DRUGS TO DRIVE SEGMENT
  • 10.5 METABOLIC DISEASES
    • 10.5.1 RISING PREVALENCE OF DIABETES AND OBESITY TO SUPPORT MARKET GROWTH
  • 10.6 INFECTIOUS DISEASES
    • 10.6.1 RECENT EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITIES FOR INFECTIOUS DISEASES
  • 10.7 IMMUNOLOGY DISEASES
    • 10.7.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
  • 10.8 OTHER DISEASES

11 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY

  • 11.1 INTRODUCTION
  • 11.2 MACHINE LEARNING
    • 11.2.1 DEEP LEARNING
      • 11.2.1.1 Reduced chance of errors in clinical trials and enhanced data consistency to augment segment growth
    • 11.2.2 SUPERVISED LEARNING
      • 11.2.2.1 Supervised learning to focus on effective patient stratification, disease progression prediction, and biomarker identification
    • 11.2.3 UNSUPERVISED LEARNING
      • 11.2.3.1 Effective handling of complex and unstructured datasets to aid adoption in trial design and execution
    • 11.2.4 REINFORCEMENT LEARNING
      • 11.2.4.1 Dynamic learning capabilities to aid adoption in personalized medicine and precision oncology
    • 11.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
  • 11.3 NATURAL LANGUAGE PROCESSING
    • 11.3.1 ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO PROPEL GROWTH IN TRIAL MANAGEMENT
  • 11.4 COMPUTER VISION
    • 11.4.1 RISING NEED FOR REPRODUCIBLE ANALYSIS IN CLINICAL ENDPOINTS TO DRIVE MARKET
  • 11.5 ROBOTIC PROCESS AUTOMATION
    • 11.5.1 ROBOTIC PROCESS AUTOMATION TO ENHANCE OPERATIONAL EFFICIENCY BY AUTOMATING ADMINISTRATIVE WORKFLOWS
  • 11.6 OTHER TECHNOLOGIES

12 AI IN CLINICAL TRIALS MARKET, BY APPLICATION

  • 12.1 INTRODUCTION
  • 12.2 BIOMARKERS
    • 12.2.1 INCREASING INVESTMENTS IN AI-BASED INNOVATION TO AID DEVELOPMENT OF PERSONALIZED HEALTHCARE SOLUTIONS
  • 12.3 CELL & GENE THERAPY
    • 12.3.1 HIGH PREVALENCE OF GENETIC DISORDERS AND TECHNOLOGICAL ADVANCEMENTS IN CAR-T THERAPIES TO DRIVE GROWTH
  • 12.4 REGENERATIVE MEDICINES
    • 12.4.1 INCREASED NEED FOR PRECISE MONITORING AND ADVANCEMENTS IN STEM CELL RESEARCH TO SPUR MARKET GROWTH
  • 12.5 MEDICAL DEVICES & DIAGNOSTICS
    • 12.5.1 NEED FOR REAL-TIME MONITORING AND REMOTE DATA ACQUISITION DURING TRIALS TO ACCELERATE MARKET GROWTH

13 AI IN CLINICAL TRIALS MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 13.2.1 HIGH R&D INVESTMENTS AND INCREASED REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH
  • 13.3 RESEARCH INSTITUTES & LABORATORIES
    • 13.3.1 INCREASED GOVERNMENT GRANTS AND COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH
  • 13.4 HEALTHCARE PROVIDERS
    • 13.4.1 ADVANCEMENTS IN PRECISION MEDICINES AND NEED FOR REAL-WORLD EVIDENCE IN CLINICAL RESEARCH TO DRIVE MARKET
  • 13.5 CONTRACT RESEARCH ORGANIZATIONS
    • 13.5.1 RISING DEMAND FOR OUTSOURCING CLINICAL TRIAL ACTIVITIES BY PHARMACEUTICAL COMPANIES TO AID MARKET GROWTH
  • 13.6 MEDICAL DEVICE MANUFACTURERS
    • 13.6.1 DEMAND FOR AI-DRIVEN DIAGNOSTICS AND MONITORING DEVICES FOR REMOTE CARE TO PROPEL MARKET GROWTH

14 AI IN CLINICAL TRIALS MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 14.2.2 US
      • 14.2.2.1 US to dominate North American AI in clinical trials market during study period
    • 14.2.3 CANADA
      • 14.2.3.1 Rising need for data standardization and increasing health expenditure to support market growth
  • 14.3 EUROPE
    • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 14.3.2 UK
      • 14.3.2.1 High R&D investment by government organizations to augment market growth
    • 14.3.3 GERMANY
      • 14.3.3.1 Increased focus on research activities and strategic developments by pharma & biotech companies to drive market
    • 14.3.4 FRANCE
      • 14.3.4.1 Strong government support and focus on domestic drug research to propel market growth
    • 14.3.5 ITALY
      • 14.3.5.1 Increased R&D investments from pharmaceutical companies and reduced time for drug approvals to fuel market growth
    • 14.3.6 SPAIN
      • 14.3.6.1 Increased technological investments by private organizations and integrated healthcare systems to spur market growth
    • 14.3.7 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 14.4.2 JAPAN
      • 14.4.2.1 Well-established clinical trial infrastructure and advanced biomedical research to support market growth
    • 14.4.3 CHINA
      • 14.4.3.1 Low cost of clinical trials and availability of treatment-naive population to propel market growth
    • 14.4.4 INDIA
      • 14.4.4.1 Favorable government policies and high R&D expenditure by Indian pharmaceutical companies to spur market growth
    • 14.4.5 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 14.5.2 BRAZIL
      • 14.5.2.1 Increasing governmental support for innovation and growing biotechnology sector to drive market
    • 14.5.3 MEXICO
      • 14.5.3.1 Strong technological and research capabilities in AI applications to fuel market growth
    • 14.5.4 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 14.6.2 GCC COUNTRIES
      • 14.6.2.1 Technological innovations and focus on precision medicines to augment market growth
    • 14.6.3 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

  • 15.1 INTRODUCTION
  • 15.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET
  • 15.3 REVENUE ANALYSIS, 2019-2023
  • 15.4 MARKET SHARE ANALYSIS, 2023
    • 15.4.1 RANKING OF KEY MARKET PLAYERS
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 15.5.1 STARS
    • 15.5.2 EMERGING LEADERS
    • 15.5.3 PERVASIVE PLAYERS
    • 15.5.4 PARTICIPANTS
    • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 15.5.5.1 Company footprint
      • 15.5.5.2 Region footprint
      • 15.5.5.3 Offering footprint
      • 15.5.5.4 Function footprint
      • 15.5.5.5 End-user footprint
  • 15.6 COMPANY EVALUATION QUADRANT: STARTUP/SMES, 2023
    • 15.6.1 PROGRESSIVE COMPANIES
    • 15.6.2 RESPONSIVE COMPANIES
    • 15.6.3 DYNAMIC COMPANIES
    • 15.6.4 STARTING BLOCKS
    • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 15.7 COMPANY EVALUATION & FINANCIAL METRICS
  • 15.8 BRAND/PRODUCT COMPARISON
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT/SERVICE/SOLUTION LAUNCHES
    • 15.9.2 DEALS
    • 15.9.3 OTHER DEVELOPMENTS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 IQVIA INC.
      • 16.1.1.1 Products/Services/Solutions offered
      • 16.1.1.2 Recent developments
        • 16.1.1.2.1 Solution launches
        • 16.1.1.2.2 Deals
      • 16.1.1.3 MnM view
        • 16.1.1.3.1 Right to win
        • 16.1.1.3.2 Strategic choices
        • 16.1.1.3.3 Weaknesses & competitive threats
    • 16.1.2 DASSAULT SYSTEMES (MEDIDATA)
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products/Services/Solutions offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Solution launches
        • 16.1.2.3.2 Deals
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Right to win
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses & competitive threats
    • 16.1.3 INSILICO MEDICINE
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products/Services/Solutions offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Other developments
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Right to win
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses & competitive threats
    • 16.1.4 TEMPUS AI, INC.
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products/Services/Solutions offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Solution launches
        • 16.1.4.3.2 Deals
        • 16.1.4.3.3 Other developments
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Right to win
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses & competitive threats
    • 16.1.5 NVIDIA CORPORATION
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products/Services/Solutions offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product and service launches
        • 16.1.5.3.2 Deals
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Right to win
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses & competitive threats
    • 16.1.6 SAAMA
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products/Services/Solutions offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Solution launches
        • 16.1.6.3.2 Deals
    • 16.1.7 PHESI
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products/Services/Solutions offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Solution launches
        • 16.1.7.3.2 Deals
    • 16.1.8 PATHAI, INC.
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products/Services/Solutions offered
    • 16.1.9 UNLEARN.AI, INC.
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products/Services/Solutions offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Solution launches
        • 16.1.9.3.2 Deals
        • 16.1.9.3.3 Other developments
    • 16.1.10 DEEP6.AI
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products/Services/Solutions offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Solution launch
        • 16.1.10.3.2 Deals
    • 16.1.11 MICROSOFT
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products/Services/Solutions offered
      • 16.1.11.3 Recent developments
    • 16.1.12 IBM
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products/Services/Solutions offered
      • 16.1.12.3 Recent developments
        • 16.1.12.3.1 Deals
    • 16.1.13 CONCERTAI
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products/Services/Solutions offered
      • 16.1.13.3 Recent developments
        • 16.1.13.3.1 Solution launches
        • 16.1.13.3.2 Deals
        • 16.1.13.3.3 Other developments
    • 16.1.14 AICURE
      • 16.1.14.1 Business overview
      • 16.1.14.2 Products/Services/Solutions offered
      • 16.1.14.3 Recent developments
        • 16.1.14.3.1 Service launches
        • 16.1.14.3.2 Deals
    • 16.1.15 MEDIAN TECHNOLOGIES
      • 16.1.15.1 Business overview
      • 16.1.15.2 Products/Services/Solutions offered
    • 16.1.16 LANTERN PHARMA INC.
      • 16.1.16.1 Business overview
      • 16.1.16.2 Products/Services/Solutions offered
      • 16.1.16.3 Recent developments
        • 16.1.16.3.1 Deals
    • 16.1.17 CITELINE, A NORSTELLA COMPANY
      • 16.1.17.1 Business overview
      • 16.1.17.2 Products/Services/Solutions offered
      • 16.1.17.3 Recent developments
        • 16.1.17.3.1 Solution launches
        • 16.1.17.3.2 Deals
    • 16.1.18 TRINETX, LLC
      • 16.1.18.1 Business overview
      • 16.1.18.2 Products/Services/Solutions offered
      • 16.1.18.3 Recent developments
        • 16.1.18.3.1 Deals
  • 16.2 OTHER PLAYERS
    • 16.2.1 REVIVEMED INC.
    • 16.2.2 EURETOS
    • 16.2.3 VERISIM LIFE
    • 16.2.4 TRIOMICS
    • 16.2.5 ARDIGEN
    • 16.2.6 QUANTHEALTH LTD.
    • 16.2.7 DEEP GENOMICS

17 APPENDIX

  • 17.1 DISCUSSION GUIDE
  • 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 17.3 CUSTOMIZATION OPTIONS
  • 17.4 RELATED REPORTS
  • 17.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 AI IN CLINICAL TRIALS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 AI IN CLINICAL TRIALS MARKET: STUDY ASSUMPTIONS
  • TABLE 3 AI IN CLINICAL TRIALS MARKET: RISK ASSESSMENT
  • TABLE 4 AI IN CLINICAL TRIALS MARKET: IMPACT ANALYSIS
  • TABLE 5 CASE STUDY 1: AI-POWERED APPROACH TO OVERCOME CHALLENGES IN IPF DRUG DEVELOPMENT
  • TABLE 6 CASE STUDY 2: REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH ADVANCED MATCHING NETWORKS
  • TABLE 7 CASE STUDY 3: BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS
  • TABLE 8 AI IN CLINICAL TRIALS MARKET: PORTER'S FIVE FORCES
  • TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
  • TABLE 10 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 11 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 NORTH AMERICA: REGULATORY FRAMEWORK
  • TABLE 13 EUROPE: REGULATORY FRAMEWORK
  • TABLE 14 ASIA PACIFIC: REGULATORY FRAMEWORK
  • TABLE 15 MIDDLE EAST & AFRICA: REGULATORY FRAMEWORK
  • TABLE 16 LATIN AMERICA: REGULATORY FRAMEWORK
  • TABLE 17 AI IN CLINICAL TRIALS MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2023-2024
  • TABLE 18 INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023
  • TABLE 19 INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022-2024
  • TABLE 20 AI IN CLINICAL TRIALS MARKET: KEY CONFERENCES & EVENTS, JANUARY 2024-DECEMBER 2025
  • TABLE 21 AI IN CLINICAL TRIALS MARKET: UNMET NEEDS
  • TABLE 22 AI IN CLINICAL TRIALS MARKET: END-USER EXPECTATIONS
  • TABLE 23 AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 24 AI IN CLINICAL TRIALS MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 25 AI IN CLINICAL TRIALS MARKET FOR NICHE SOLUTIONS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 26 AI IN CLINICAL TRIALS MARKET FOR TECHNOLOGY PROVIDERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 27 AI IN CLINICAL TRIALS MARKET FOR SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 28 CONSULTING SERVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 29 IMPLEMENTATION SERVICES & OUTGOING IT SUPPORT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 30 TRAINING & EDUCATION SERVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 31 POST-SALES & MAINTENANCE SERVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 32 AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 33 AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 34 AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 35 PATIENT IDENTIFICATION & SCREENING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 36 PATIENT ENGAGEMENT & RETENTION MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 37 SITE OPTIMIZATION MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 38 AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 39 AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 40 AI IN CLINICAL TRIALS MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 41 AI IN CLINICAL TRIALS MARKET FOR PREDICTIVE MODELING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 42 AI IN CLINICAL TRIALS MARKET FOR RISK MANAGEMENT, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 43 AI IN CLINICAL TRIALS MARKET FOR DATA MANAGEMENT & QUALITY CONTROL, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 44 AI IN CLINICAL TRIALS MARKET FOR ADVERSE EVENT PREDICTION & DETECTION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 45 AI IN CLINICAL TRIALS MARKET FOR DRUG REPURPOSING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 46 AI IN CLINICAL TRIALS MARKET FOR REGULATORY COMPLIANCE, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 47 AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 48 AI IN PHASE 1 CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 49 AI IN PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 50 AI IN PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 51 AI IN PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 52 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 53 AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 54 AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 55 PUBLIC CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 56 PRIVATE CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 57 MULTI CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 58 HYBRID CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 59 AI IN CLINICAL TRIALS MARKET FOR ON-PREMISES SOLUTIONS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 60 AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 61 AI IN CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 62 AI IN CLINICAL TRIALS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 63 AI IN CLINICAL TRIALS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 64 AI IN CLINICAL TRIALS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 65 AI IN CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 66 AI IN CLINICAL TRIALS MARKET FOR IMMUNOLOGY DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 67 AI IN CLINICAL TRIALS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 68 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 69 AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 70 AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 71 DEEP LEARNING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 72 SUPERVISED LEARNING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 73 UNSUPERVISED LEARNING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 74 REINFORCEMENT LEARNING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 75 OTHER MACHINE LEARNING TECHNOLOGIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 76 AI IN CLINICAL TRIALS MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 77 AI IN CLINICAL TRIALS MARKET FOR COMPUTER VISION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 78 AI IN CLINICAL TRIALS MARKET FOR ROBOTIC PROCESS AUTOMATION, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 79 AI IN CLINICAL TRIALS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 80 AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 81 AI IN CLINICAL TRIALS MARKET FOR BIOMARKERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 82 AI IN CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 83 AI IN CLINICAL TRIALS MARKET FOR REGENERATIVE MEDICINES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 84 AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICES & DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 85 AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 86 AI IN CLINICAL TRIALS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 87 AI IN CLINICAL TRIALS MARKET FOR RESEARCH INSTITUTES & LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 88 AI IN CLINICAL TRIALS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 89 RECENT ACQUISITIONS /COLLABORATIONS WITH CONTRACT RESEARCH ORGANIZATIONS
  • TABLE 90 AI IN CLINICAL TRIALS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 91 AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 92 AI IN CLINICAL TRIALS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 93 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 97 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 98 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 99 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 100 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 101 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 102 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
  • TABLE 103 US: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 104 US: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 105 US: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 106 US: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 107 US: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 108 US: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 109 US: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 110 US: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 111 CANADA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 112 CANADA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 113 CANADA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 114 CANADA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 115 CANADA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 116 CANADA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 117 CANADA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 118 CANADA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 119 EUROPE: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 120 EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 121 EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 122 EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 123 EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 124 EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 125 EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 126 EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 127 EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 128 UK: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 129 UK: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 130 UK: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 131 UK: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 132 UK: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 133 UK: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 134 UK: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 135 UK: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 136 GERMANY: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 137 GERMANY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 138 GERMANY: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 139 GERMANY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 140 GERMANY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 141 GERMANY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 142 GERMANY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 143 GERMANY: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 144 FRANCE: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 145 FRANCE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 146 FRANCE: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 147 FRANCE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 148 FRANCE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 149 FRANCE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 150 FRANCE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 151 FRANCE: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 152 ITALY: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 153 ITALY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 154 ITALY: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 155 ITALY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 156 ITALY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 157 ITALY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 158 ITALY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 159 ITALY: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 160 SPAIN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 161 SPAIN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 162 SPAIN: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 163 SPAIN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 164 SPAIN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 165 SPAIN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 166 SPAIN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 167 SPAIN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 168 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 169 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 170 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 171 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 172 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 173 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 174 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 175 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 176 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 178 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 185 JAPAN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 186 JAPAN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 187 JAPAN: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 188 JAPAN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 189 JAPAN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 190 JAPAN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 191 JAPAN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 192 JAPAN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 193 CHINA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 194 CHINA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 195 CHINA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 196 CHINA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 197 CHINA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 198 CHINA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 199 CHINA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 200 CHINA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 201 INDIA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 202 INDIA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 203 INDIA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 204 INDIA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 205 INDIA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 206 INDIA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 207 INDIA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 208 INDIA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 209 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 210 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 211 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 212 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 213 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 214 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 215 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 216 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 217 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 218 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 219 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 220 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 221 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 222 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 223 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 224 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 225 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 226 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 227 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 228 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 229 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 230 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 231 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 232 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 233 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 234 MEXICO: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 235 MEXICO: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 236 MEXICO: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 237 MEXICO: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 238 MEXICO: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 239 MEXICO: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 240 MEXICO: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 241 MEXICO: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 242 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 243 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 244 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 245 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 246 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 247 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 248 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 249 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 250 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 251 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 252 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 253 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 254 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 255 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 256 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 257 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 258 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 259 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 260 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 261 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 262 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 263 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 264 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 265 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 266 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 267 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
  • TABLE 268 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
  • TABLE 269 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
  • TABLE 270 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
  • TABLE 271 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 272 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 273 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
  • TABLE 274 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 275 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET
  • TABLE 276 AI IN CLINICAL TRIALS MARKET: DEGREE OF COMPETITION
  • TABLE 277 AI IN CLINICAL TRIALS MARKET: REGION FOOTPRINT
  • TABLE 278 AI IN CLINICAL TRIALS MARKET: OFFERING FOOTPRINT
  • TABLE 279 AI IN CLINICAL TRIALS MARKET: FUNCTION FOOTPRINT
  • TABLE 280 AI IN CLINICAL TRIALS MARKET: END-USER FOOTPRINT
  • TABLE 281 AI IN CLINICAL TRIALS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 282 AI IN CLINICAL TRIALS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 283 AI IN CLINICAL TRIALS MARKET: PRODUCT/SERVICE/SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 284 AI IN CLINICAL TRIALS MARKET: DEALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 285 AI IN CLINICAL TRIALS MARKET: OTHER DEVELOPMENTS, JANUARY 2021- NOVEMBER 2024
  • TABLE 286 IQVIA INC.: COMPANY OVERVIEW
  • TABLE 287 IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 288 IQVIA INC.: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 289 IQVIA INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 290 DASSAULT SYSTEMES (MEDIDATA): COMPANY OVERVIEW
  • TABLE 291 DASSAULT SYSTEMES (MEDIDATA): PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 292 DASSAULT SYSTEMES (MEDIDATA): SOLUTION LAUNCHES, JANUARY 2021- NOVEMBER 2024
  • TABLE 293 DASSAULT SYSTEMES (MEDIDATA): DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 294 INSILICO MEDICINE: COMPANY OVERVIEW
  • TABLE 295 INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 296 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 297 TEMPUS AI, INC.: COMPANY OVERVIEW
  • TABLE 298 TEMPUS AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 299 TEMPUS AI, INC.: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 300 TEMPUS AI, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 301 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 302 NVIDIA CORPORATION: COMPANY OVERVIEW
  • TABLE 303 NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 304 NVIDIA CORPORATION: PRODUCT AND SERVICE LAUNCHES, JANUARY 2021- NOVEMBER 2024
  • TABLE 305 NVIDIA CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 306 SAAMA: COMPANY OVERVIEW
  • TABLE 307 SAAMA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 308 SAAMA: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 309 SAAMA.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 310 PHESI: COMPANY OVERVIEW
  • TABLE 311 PHESI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 312 PHESI: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 313 PHESI: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 314 PATHAI, INC.: COMPANY OVERVIEW
  • TABLE 315 PATHAI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 316 UNLEARN.AI, INC.: COMPANY OVERVIEW
  • TABLE 317 UNLEARN.AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 318 UNLEARN.AI, INC.: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 319 UNLEARN.AI, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 320 UNLEARN.AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
  • TABLE 321 DEEP6.AI: COMPANY OVERVIEW
  • TABLE 322 DEEP6.AI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 323 DEEP6.AI: SOLUTION LAUNCH, JANUARY 2021-NOVEMBER 2024
  • TABLE 324 DEEP6.AI: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 325 MICROSOFT: COMPANY OVERVIEW
  • TABLE 326 MICROSOFT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 327 MICROSOFT CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 328 IBM: COMPANY OVERVIEW
  • TABLE 329 IBM: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 330 IBM: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 331 CONCERTAI: COMPANY OVERVIEW
  • TABLE 332 CONCERTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 333 CONCERTAI: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 334 CONCERTAI: DEALS, JANUARY 2021- NOVEMBER 2024
  • TABLE 335 CONCERTAI: OTHER DEVELOPMENTS, JANUARY 2021- NOVEMBER 2024
  • TABLE 336 AICURE: COMPANY OVERVIEW
  • TABLE 337 AICURE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 338 AICURE: SERVICE LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 339 AICURE: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 340 MEDIAN TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 341 MEDIAN TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 342 LANTERN PHARMA INC.: COMPANY OVERVIEW
  • TABLE 343 LANTERN PHARMA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 344 LANTERN PHARMA INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 345 CITELINE, A NORSTELLA COMPANY: COMPANY OVERVIEW
  • TABLE 346 CITELINE, A NORSTELLA COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 347 CITELINE, A NORSTELLA COMPANY: SOLUTION LAUNCHES, JANUARY 2021- NOVEMBER 2024
  • TABLE 348 CITELINE, A NORSTELLA COMPANY: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 349 TRINETX, LLC: COMPANY OVERVIEW
  • TABLE 350 TRINETX, LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 351 TRINETX, LLC: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 352 REVIVEMED INC.: COMPANY OVERVIEW
  • TABLE 353 EURETOS: COMPANY OVERVIEW
  • TABLE 354 VERISIM LIFE: COMPANY OVERVIEW
  • TABLE 355 TRIOMICS: COMPANY OVERVIEW
  • TABLE 356 ARDIGEN: COMPANY OVERVIEW
  • TABLE 357 QUANTHEALTH LTD.: COMPANY OVERVIEW
  • TABLE 358 DEEP GENOMICS: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 AI IN CLINICAL TRIALS MARKET: SEGMENTS CONSIDERED
  • FIGURE 2 AI IN CLINICAL TRIALS MARKET: YEARS CONSIDERED
  • FIGURE 3 AI IN CLINICAL TRIALS MARKET: RESEARCH DESIGN
  • FIGURE 4 AI IN CLINICAL TRIALS MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 AI IN CLINICAL TRIALS MARKET: KEY PRIMARY SOURCES
  • FIGURE 6 AI IN CLINICAL TRIALS MARKET: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 7 AI IN CLINICAL TRIALS MARKET: KEY INSIGHTS FROM PRIMARIES
  • FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 9 MARKET SIZE ESTIMATION: SUPPLY-SIDE REVENUE SHARE ANALYSIS
  • FIGURE 10 AI IN CLINICAL TRIALS MARKET: TOP-DOWN APPROACH
  • FIGURE 11 AI IN CLINICAL TRIALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 13 AI IN CLINICAL TRIALS MARKET: DATA TRIANGULATION
  • FIGURE 14 AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2024 VS. 2030 (USD MILLION)
  • FIGURE 15 AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2024 VS. 2030 (USD MILLION)
  • FIGURE 16 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 17 AI IN CLINICAL TRIALS MARKET, BY PHASE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 18 AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION)
  • FIGURE 19 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2024 VS. 2030 (USD MILLION)
  • FIGURE 20 AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2024 VS. 2030 (USD MILLION)
  • FIGURE 21 AI IN CLINICAL TRIALS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
  • FIGURE 22 AI IN CLINICAL TRIALS MARKET: REGIONAL SNAPSHOT
  • FIGURE 23 NEED FOR DATA STANDARDIZATION AND FAVORABLE GOVERNMENT POLICIES TO DRIVE MARKET
  • FIGURE 24 NORTH AMERICA TO DOMINATE AI IN CLINICAL TRIALS MARKET DURING FORECAST PERIOD
  • FIGURE 25 US AND PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
  • FIGURE 26 UK TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
  • FIGURE 27 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATES FROM 2024 TO 2029
  • FIGURE 28 AI IN CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 29 APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2015-2023
  • FIGURE 30 HEALTHCARE SECURITY BREACHES OF 500+ RECORDS (2009-2023)
  • FIGURE 31 AI IN CLINICAL TRIALS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 32 AI IN CLINICAL TRIALS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 33 AI IN CLINICAL TRIALS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 34 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
  • FIGURE 35 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 36 PATENT PUBLICATION TRENDS IN AI IN CLINICAL TRIALS MARKET, 2015-2024
  • FIGURE 37 TOP APPLICANTS/OWNERS OF PATENTS AND NUMBER OF PATENTS GRANTED, JANUARY 2015-NOVEMBER 2024
  • FIGURE 38 AI IN CLINICAL TRIALS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • FIGURE 39 AI IN CLINICAL TRIALS MARKET: FUNDING AND NUMBER OF DEALS, 2022-2024
  • FIGURE 40 IMPACT OF AI/GEN AI ON AI-BASED CLINICAL TRIAL SOLUTIONS
  • FIGURE 41 IMPACT OF GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
  • FIGURE 42 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET SNAPSHOT
  • FIGURE 43 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET SNAPSHOT
  • FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET, 2019-2023 (USD BILLION)
  • FIGURE 45 MARKET SHARE ANALYSIS IN AI IN CLINICAL TRIALS MARKET (2023)
  • FIGURE 46 RANKING OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET (2023)
  • FIGURE 47 AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 48 AI IN CLINICAL TRIALS MARKET: COMPANY FOOTPRINT
  • FIGURE 49 AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 50 EV/EBITDA OF KEY VENDORS
  • FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN CLINICAL TRIAL KEY VENDORS
  • FIGURE 52 AI IN CLINICAL TRIALS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 53 IQVIA INC.: COMPANY SNAPSHOT
  • FIGURE 54 DASSAULT SYSTEMES (MEDIDATA): COMPANY SNAPSHOT
  • FIGURE 55 NVIDIA CORPORATION: COMPANY SNAPSHOT
  • FIGURE 56 MICROSOFT: COMPANY SNAPSHOT
  • FIGURE 57 IBM: COMPANY SNAPSHOT
  • FIGURE 58 MEDIAN TECHNOLOGIES: COMPANY SNAPSHOT